Role of endogenous GLP-1 and GIP in beta cell compensatory responses to insulin resistance and cellular stress

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Vasu, Srividya ^a   Moffett, R Charlotte ^a   Thorens, Bernard ^b   Flatt, Peter R ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; HORMONE RECEPTOR; HYDROCORTISONE; INCRETIN; INCRETIN RECEPTOR; STREPTOZOCIN; UNCLASSIFIED DRUG; HORMONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL EXPANSION; CELL SIZE; CELLULAR DISTRIBUTION; CELLULAR STRESS RESPONSE; CONTROLLED STUDY; HORMONE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INSULIN RELEASE; INSULIN RESISTANCE; MALE; MOUSE; NONHUMAN; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; ANIMAL; APOPTOSIS; BLOOD; CELL PROLIFERATION; DRUG EFFECTS; KNOCKOUT MOUSE; LYMPHOCYTE; METABOLISM; PANCREAS; PANCREAS ISLET; PATHOLOGY; PROTEIN TRANSPORT;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HORMONES; HYDROCORTISONE; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS; LYMPHOCYTES; MALE; MICE; MICE, KNOCKOUT; PANCREAS; PROTEIN TRANSPORT; STREPTOZOCIN;

EID: 84903398933     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101005     Document Type: Article

References (45)

1. Drucker DJ (2007) The role of gut hormones in glucose homeostasis. J Clin Invest 117: 24-32.
2. Green BD, Flatt PR (2007) Incretin hormone mimetics and analogues in diabetes therapeutics. Best Pract Res Clin Endocrinol Metab 21: 497-516. (Pubitemid 350177567)
3. Holst JJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev 87: 1409-1439.
4. McIntosh CH, Widenmaier S, Kim SJ (2009) Glucose-dependent insulinotropic polypeptide (Gastric Inhibitory Polypeptide; GIP). Vitam Horm 80: 409-471.
5. Irwin N, Gault V, Flatt PR (2010) Therapeutic potential of the original incretin hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity, osteoporosis and Alzheimer's disease? Expert Opin Investig Drugs 19: 1039-1048.
6. Irwin N, Flatt PR (2009) Therapeutic potential for GIP receptor agonists and antagonists. Best Pract Res Clin Endocrinol Metab 23: 499-512.
7. Barnett AH, O'Hare P (2013) Cardiovascular benefits of incretins. BMJ 347: f4382.
8. Campbell JE, Drucker DJ (2013) Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 17: 819-837.
9. Irwin N, Flatt PR (2013) Enteroendocrine hormone mimetics for the treatment of obesity and diabetes. Curr Opin Pharmacol 13: 989-995.
10. Nauck MA, Baranov O, Ritzel RA,Meier JJ (2013) Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation? Diabetologia 56: 1878-1883.
11. Flatt PR, Bailey CJ, Green BD (2009) Recent advances in antidiabetic drug therapies targeting the enteroinsular axis. Curr Drug Metab 10: 125-137.
12. Heller RS, Aponte GW (1995) Intra-islet regulation of hormone secretion by glucagon-like peptide-1-(7-36) amide. Am J Physiol 269: G852-60.
13. Masur K, Tibaduiza EC, Chen C, Ligon B, Beinborn M (2005) Basal receptor activation by locally produced glucagon-like peptide-1 contributes to maintaining beta-cell function. Mol Endocrinol 19: 1373-1382. (Pubitemid 40594131)
14. Hansen AM, Bodvarsdottir TB, Nordestgaard DN, Heller RS, Gotfredsen CF, et al. (2011) Upregulation of alpha cell glucagon-like peptide 1 (GLP-1) in Psammomys obesus-an adaptive response to hyperglycaemia? Diabetologia 54: 1379-1387.
15. Whalley NM, Pritchard LE, Smith DM, White A (2011) Processing of proglucagon to GLP-1 in pancreatic alpha-cells: is this a paracrine mechanism enabling GLP-1 to act on beta-cells? J Endocrinol 211: 99-106.
16. Marchetti P, Lupi R, Bugliani M, Kirkpatrick CL, Sebastiani G, et al. (2012) A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets. Diabetologia 55: 3262-3272.
17. Thyssen S, Arany E, Hill DJ (2006) Ontogeny of regeneration of beta-cells in the neonatal rat after treatment with streptozotocin. Endocrinology 147: 2346-2356.
18. Ellingsgaard H, Hauselmann I, Schuler B, Habib AM, Baggio LL, et al. (2011) Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med 17: 1481-1489.
19. Irwin N, Montgomery IA, Moffett RC, Flatt PR (2013) Chemical cholecystokinin receptor activation protects against obesity-diabetes in high fat fed mice and has sustainable beneficial effects in genetic ob/ob mice. Biochem Pharmacol 85: 81-91.
20. Salehi M, Aulinger B, Prigeon RL, D'Alessio DA (2010) Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes. Diabetes 59: 1330-1337.
21. Fujita Y, Wideman RD, Asadi A, Yang GK, Baker R, et al. (2010) Glucose-dependent insulinotropic polypeptide is expressed in pancreatic islet alpha-cells and promotes insulin secretion. Gastroenterology 138: 1966-1975.
22. Ugleholdt R, Poulsen ML, Holst PJ, Irminger JC, Orskov C, et al. (2006) Prohormone convertase 1/3 is essential for processing of the glucose-dependent insulinotropic polypeptide precursor. J Biol Chem 281: 11050-11057. (Pubitemid 43855528)
23. Gault VA, Porter DW, Irwin N, Flatt PR (2011) Comparison of sub-chronic metabolic effects of stable forms of naturally occurring GIP (1-30) and GIP (1-42) in high-fat fed mice. J Endocrinol 208: 265-271.
24. Mojsov S, Kopczynski MG, Habener JF (1990) Both amidated and nonamidated forms of glucagon-like peptide I are synthesized in the rat intestine and the pancreas. J Biol Chem 265: 8001-8008.
25. Eissele R, Goke R, Willemer S, Harthus HP, Vermeer H, et al. (1992) Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest 22: 283-291.
26. Nie Y, Nakashima M, Brubaker PL, Li QL, Perfetti R, et al. (2000) Regulation of pancreatic PC1 and PC2 associated with increased glucagon-like peptide 1 in diabetic rats. J Clin Invest 105: 955-965. (Pubitemid 30203068)
27. Wideman RD, Covey SD, Webb GC, Drucker DJ, Kieffer TJ (2007) A switch from prohormone convertase (PC)-2 to PC1/3 expression in transplanted alpha-cells is accompanied by differential processing of proglucagon and improved glucose homeostasis in mice. Diabetes 56: 2744-2752. (Pubitemid 350044917)
28. Kilimnik G, Kim A, Steiner DF, Friedman TC, Hara M (2010) Intraislet production of GLP-1 by activation of prohormone convertase 1/3 in pancreatic alpha-cells in mouse models of ss-cell regeneration. Islets 2: 149-155.
29. Baggio LL, Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132: 2131-2157. (Pubitemid 46711096)
30. Irwin N, McClean PL, Hunter K, Flatt PR (2009) Metabolic effects of sustained activation of the GLP-1 receptor alone and in combination with background GIP receptor antagonism in high fat-fed mice. Diabetes Obes Metab 11: 603-610.
31. Scrocchi LA, Brown TJ, MaClusky N, Brubaker PL, Auerbach AB, et al. (1996) Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 2: 1254-1258. (Pubitemid 26375413)
32. Preitner F, Ibberson M, Franklin I, Binnert C, Pende M, et al. (2004) Glucoincretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors. J Clin Invest 113: 635-645. (Pubitemid 38542513)
33. Flatt PR, Bailey CJ (1981) Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice. Diabetologia 20: 573-577. (Pubitemid 11096955)
34. Calcinaro F, Dionisi S, Marinaro M, Candeloro P, Bonato V, et al. (2005) Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse. Diabetologia 48: 1565-1575. (Pubitemid 41175510)
35. Kelly C, McClenaghan NH, Flatt PR (2011) Role of islet structure and cellular interactions in the control of insulin secretion. Islets 3: 41-47.
36. Creutzfeldt W (2001) The entero-insular axis in type 2 diabetes-incretins as therapeutic agents. Exp Clin Endocrinol Diabetes 109 Suppl 2: S288-303.
37. Flatt PR, Bailey CJ, Green BD (2008) Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes. Front Biosci 13: 3648-3660. (Pubitemid 351594649)
38. O'Brien BA, Harmon BV, Cameron DP, Allan DJ (1996) Beta-cell apoptosis is responsible for the development of IDDM in the multiple low-dose streptozotocin model. J Pathol 178: 176-181. (Pubitemid 26059918)
39. Takeda Y, Fujita Y, Honjo J, Yanagimachi T, Sakagami H, et al. (2012) Reduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice. Diabetologia 55: 404-412.
40. Hansotia T, Drucker DJ (2005) GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice. Regul Pept 128: 125-134. (Pubitemid 40380913)
41. Bailey CJ, Flatt PR (1982) Hormonal control of glucose homeostasis during development and ageing in mice. Metabolism 31: 238-246. (Pubitemid 12176911)
42. Swali A, Walker EA, Lavery GG, Tomlinson JW, Stewart PM (2008) 11beta-Hydroxysteroid dehydrogenase type 1 regulates insulin and glucagon secretion in pancreatic islets. Diabetologia 51: 2003-2011.
43. Nadal A, Alonso-Magdalena P, Soriano S, Ropero AB, Quesada I (2009) The role of oestrogens in the adaptation of islets to insulin resistance. J Physiol 587: 5031-5037.
44. Thorens B (2013) The required beta cell research for improving treatment of type 2 diabetes. J Intern Med 274: 203-214.
45. Kaiser D, Oetjen E (2014) Something old, something new, and something very old - drugs for treating type 2 diabetes. Br J Pharmacol.